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Virus productionAleutian Mink Disease Virus (AMDV) is the only virus in the genus Amdovirus of family Parvoviridae. In adult
mink, AMDV causes a persistent infection associated with severe dysfunction of the immune system. Cleav-
age of AMDV capsid proteins has been previously shown to play a role in regulating progeny virus production
(Fang Cheng et al., J. Virol. 84:2687–2696, 2010). The present study shows that AMDV has evolved a second
strategy to limit expression of capsid proteins by preventing processing of the full-length capsid protein-
encoding mRNA transcripts. Characterization of the cis-elements of the proximal polyadenylation site
[(pA)p] in the infectious clone of AMDV revealed that polyadenylation at the (pA)p site is controlled by
an upstream element (USE) of 200 nts in length, the AAUAAA signal, and a downstream element (DSE)
of 40 nts. A decrease in polyadenylation at the (pA)p site, either by mutating the AAUAAA signal or the
DSE, which does not affect the encoding of amino acids in the infectious clone, increased the expression
of capsid protein VP1/VP2 and thereby increased progeny virus production approximately 2–3-fold. This
increase was accompanied by enhanced replication of the AMDV genome. Thus, this study reveals correla-
tions among internal polyadenylation, capsid production, viral DNA replication and progeny virus produc-
tion of AMDV, indicating that internal polyadenylation is a limiting step for parvovirus replication and
progeny virus production.
© 2012 Elsevier Inc. All rights reserved.Introduction
Aleutian Mink Disease Virus (AMDV) is the only virus in the genus
Amdovirus, in the family Parvoviridae (Fauquet et al., 2005). Disease
manifestations caused by AMDV vary in animals of different ages. In
neonatal mink kits, AMDV infection causes acute, rapidly progressing
interstitial pneumonia with a high mortality rate (Alexandersen,
1990). In adult mink, however, AMDV infection is characterized by
glomerulonephritis, plasmacytosis, hypergammaglobinemia, arteritis,
decreased fertility, and spontaneous abortion (Alexandersen et al.,
1994; Gorham et al., 1976). Aleutian mink disease is the most signif-
icant infectious disease affecting mink farming worldwide and it has
becoming a limiting factor in the production of mink in some areas
(Newman and Reed, 2006). Notably, a recent study reported that
AMDV may be a zoonotic disease capable of infecting humans
(Jepsen et al., 2009).
AMDV shares many features with other parvoviruses, including
members of the genera Erythrovirus [human parvovirus B19 (B19V)]logy, Molecular Genetics and
ail Stop 3029, 3901 Rainbow
5.
rights reserved.and Bocavirus [minute virus of canines (MVC), and human bocavirus
(HBoV)]. AMDV has a single-stranded DNA (ssDNA) genome of
4.7 kb. A single pre-mRNA is transcribed from the P3 promoter and
this generates six mRNA transcripts through alternative splicing and
alternative polyadenylation (Qiu et al., 2006a) (Fig. 1). Only the
mRNA transcripts that read through the proximal polyadenylation
site [(pA)p] are capable of encoding the capsid proteins VP1 and
VP2. The R2 mRNA, which is spliced from the D1 donor to the A2 ac-
ceptor and from the D3 donor to the A3 acceptor, encodes both the
VP1 and VP2 capsid protein (Qiu et al., 2007b). Alternative polyade-
nylation is utilized commonly during pre-mRNA processing of parvo-
viruses (Qiu et al., 2006b). It is especially important in members of
the genera Amdovirus, Erythrovirus and Bocavirus in that only one
pre-mRNA is transcribed, which has to read through the internal
polyadenylation site in order to generate full-length capsid protein-
encoding mRNA transcripts (Liu et al., 2004; Ozawa et al., 1987; Qiu
et al., 2007a; Sun et al., 2009). Block of the full-length mRNA tran-
script production has been suggested to be a limiting step in B19V
infection of permissive cells (Liu et al., 1992). We have shown that
replication of the B19V genome in permissive cells or “artiﬁcial” rep-
lication of the B19V genome supported by a heterogeneous replica-
tion origin can overcome this block, resulting in a signiﬁcantly
increased level of B19V capsid protein-encoding mRNA transcripts
Fig. 1. Genetic map of AMDV.The genome of AMDV-G is depicted to scale with indicated transcription units, including the hairpin terminal repeats (TR), P3 promoter, splice donor
site (D1, D2, and D3), splice acceptor sites (A1, A2, and A3), internal proximal polyadenylation site [(pA)p], and internal distal polyadenylation site [(pA)d]. Six major mRNA tran-
scripts are shown with R1-3 polyadenylated at the (pA)d site and R1′–3′ polyadenylated at the (pA)p site. The AMDV-G proteins NS1, NS2, NS3 (only putative) and VP1/VP2
encoded from each RNA are indicated.
168 Q. Huang et al. / Virology 426 (2012) 167–177(Guan et al., 2008). However, the exact function of internal polyade-
nylation in parvovirus replication has not been investigated in the
context of an infectious clone.
Aleutian mink disease is an immune complex-mediated disease
associated with persistent infection in adult mink (Best and Bloom,
2005b; Bloom et al., 1975; Eklund et al., 1968). Control of capsid pro-
tein production has been shown to govern the persistence of AMDV in
infected host animals (Alexandersen et al., 1988; Christensen et al.,
1993; Storgaard et al., 1993, 1997), which likely requires controlled
low levels of capsid proteins. We have previously demonstrated that
capsid proteins of AMDV are cleaved at a speciﬁc site of 417DLLD/
G421 by caspases during infection (Cheng et al., 2009). Mutations of
this site increase expression levels of VP1 and VP2, as well as progeny
virus production. We hypothesize that the cleavage (or reduction) of
capsid proteins limits packaging of the viral ssDNA genome, and that
this cleavage is likely to be important for the maintenance of persis-
tent infection and restriction of AMDV replication in infected mink,
in which a low level of viral DNA replication is balanced during in
vivo AMDV infection of mink. This mechanism contributes to persis-
tent infection of AMDV in adult mink in addition to the fact that
AMDV is poorly neutralized by antibodies generated during in vivo
infection (Best and Bloom, 2005a).
The current study explores the relationships among internal poly-
adenylation, virus DNA replication, capsid protein expression and
progeny virus production of AMDV in the context of an AMDV infec-
tious clone. The cis-elements located in the internal polyadenylation
site were characterized and it was found that the prevention of inter-
nal polyadenylation increased capsid protein expression as well as
the replication of the AMDV genome, increasing the production of
progeny virus. This is the ﬁrst study to show such a relationship in
the context of a parvovirus infectious clone.Results
The transcription proﬁle of the CMV promoter-driven non-replicative
AMDV-G genome is comparable to that of infectious virus in CrFK cells
To characterize the internal polyadenylation site of AMDV, the P3
promoter was replaced with a CMV promoter. This initiated tran-
scription of nt 180–4533 of the AMDV genome, which includes NS1-
and capsid protein-encoding regions and the distal polyadenylation
site [(pA)d)] (Fig. 2A). RNAs were generated from the transfection
of the construct CMV-NSCap and compared with those generated
from AMDV-G infection in CrFK cells. Comparisons were carried out
through RNase protection assays using seven anti-sense RNA probes
(Fig. 2A) (Qiu et al., 2006a). The levels of protection of AMDV
mRNA transcripts in the CMV-NSCap-transfected and AMDV-G-
infected CrFK were similar to those determined previously (Fig. 2B)
(Qiu et al., 2006a). For example, the probe P(pA)p probe protected
read-through (RT) RNA vs. RNA polyadenylated at the (pA)p site
[(pA)p] in transfected cells at a ratio of ~3:1, which is approximately
the same as the ratio seen during virus infection (Fig. 2B, compare
lanes 13 to 14). Thus, it was decided to use transfection with the
CMV-NSCap construct for identifying cis-elements lying in the (pA)p
site.
Characterization of cis-elements in the internal polyadenylation site
of AMDV
A core polyadenylation signal is comprised of an upstream ele-
ment (USE), the core AAUAAA site, and a downstream element
(DSE) (Zhao et al., 1999). To identify the DSE at the AMDV (pA)p
site, a series of mutations were introduced in the region downstream
Fig. 2. RNAs produced from the transfection of a non-replicative AMDV genome are processed similarly to those produced during AMDV-G infection.(A) Schematic diagram of the
AMDV genome and the probes used for the RNase protection assay (RPA). The landmarks of transcription are shown. The RPA probes PD1, PA1, PD2, PA2, PD3, PA3 and p(pA)p are
shown along with their nucleotide numbers (numbering is according to Genbank accession no. JN040434). Bands from each probe that were expected to be protected are shown
with sizes under their corresponding region in the genome. Spl, spliced RNAs; Unspl, unspliced RNAs; RT, RNAs resulting from read-through of the (pA)p site; (pA)p, RNAs poly-
adenylated RNAs at (pA)p. (B) RPA analysis. Ten μg of total RNA isolated from CMV-NSCap-transfected and AMDV-infected CrFK cells was used for the RPA analysis, along with the
above described probes, in individual reactions as indicated. Lane 1, 32P-labeled RNA markers (Qiu et al., 2002), with sizes indicated to the left.
169Q. Huang et al. / Virology 426 (2012) 167–177of the (pA)p site, spanning nt 2544-2743. In CMV-NSCap, deletion of
the whole region (DSE1–200) abolished polyadenylation at the (pA)p
site, as did deletion of the ﬁrst 100 nts (DSE 1–100), but deletion of
the second 100-nts (DSE101-200) did not affect polyadenylation.
This narrowed the location of the DSE down to the ﬁrst 100 nts
(Fig. 3B, lanes 3 and 4). The sequence of nt 2583–2612 was further
mutated (41 and 69 nts after nt 2544, respectively) and nt 2613–2643
was mutated (70 and 100 nts after nt 2544, respectively). Neither
of these mutations affected polyadenylation at the (pA)p site, which
remained at a level comparable to that of the wild type in both CMV-
NSCap(mDSE41-69) and CMV-NSCap(mDSE70-100) (Fig. 3B, lanes
5 and 7 vs. 1). However, further mutations in the region 40 nts down-
stream of the (pA)p site either abolished or signiﬁcantly reduced poly-
adenylation at (pA)p (Fig. 3A, lanes 9–13). We conclude that the cis-
sequence of nt 2544–2583 (40-nts), immediately downstream of the
(pA)p site, is critical for polyadenylation of AMDV mRNA transcripts
to be polyadenylated at the (pA)p site, which functions as a DSE
(Zarudnaya et al., 2003).
To identify the USE, we made a series of mutations in the region
spanning nt 2324–2523 upstream of the (pA)p site. Only the complete
mutation of all 200-nts abolished the polyadenylation of AMDV pre-
mRNA at the (pA)p site (Fig. 4B, lane 2). Further mutations in this
200 nts sequence, in the downstream half of the region, reducedpolyadenylation at the (pA)p site only slightly, from ~40% to ~10–20%
(Fig. 4B, lane 2 vs. lanes 4–6). Mutations in the upstream half of the re-
gion did not reduce polyadenylation at the (pA)p site signiﬁcantly
(Fig. 4B, lane 3). We conclude that the cis-sequence at nt 2324–2523
(200-nts), upstream of the (pA)p site, plays a role as the USE for efﬁ-
cient polyadenylation of AMDV mRNA transcripts at the (pA)p site.
Knockdown of the core polyadenylation signal AAUAAA in an AMDV-G
infectious clone increases replication of the AMDV genome and progeny
virus production
The core polyadenylation signal AAUAAA, which binds to cleavage
and polyadenylation speciﬁc factor 1 (CPSF160), is the key element in
mammalian mRNA polyadenylation (Zhao et al., 1999). A series of
mutations in this hexanucleotide were made and ﬁve mutant con-
structs were created on CMV-NSCap. None of the ﬁve mutants pro-
duced detectable mRNA transcripts polyadenylated at the (pA)p site
(Fig. 5B, lane 1. vs. 2–6), supporting the key role of this hexanucleo-
tide in the internal polyadenylation of AMDV mRNA transcripts. It
was also observed that the levels of capsid proteins VP1 and VP2
expressed from these mutants were increased ~2-fold compared
with those of the wild type (Fig. 5C, lane 2. vs. 3–7). These same
mutations of the AAUAAA were then introduced into an AMDV
Fig. 3. Identiﬁcation of the DSE of the AMDV internal polyadenylation site.(A) Schematic diagram of mutations downstream of the (pA)p site. The AMDV genome is shown, along
with its transcription units. Mutations in the region of nt 2544–2473 are diagrammed, with detailed sequences described in Materials and methods. The P(pA)p probe is shown.
(B) RPA analysis. Ten μg of total RNA isolated after two days from CMV-NSCap- or its mutant-transfected CrFK cells was used for protection by the probe P(pA)p or its homology
probes. The origins of the two protected bands in the lanes are indicated to the right.
170 Q. Huang et al. / Virology 426 (2012) 167–177infectious clone (pIAMDV) (Cheng et al., 2009). Transfection of the
pIAMDV-based AAUAAA mutants also failed to produce AMDV mRNA
transcripts polyadenylated at the (pA)p site (data not shown). This
suggested that only three AMDV mRNA transcripts (R1–3) that are
polyadenylated at the (pA)d site are produced (Fig. 5A).
Next, viral DNA replication, capsid protein expression, and progeny
virus production from transfected pIAMDV-based AAUAAA mutants
were examined. AMDV-G replicates optimally in CrFK cells maintained
at a low temperature of 31.8 °C, and a fully productive infection takes
places over the course of six–seven days (Bloom et al., 1994; Qiu et al.,
2006a). Therefore, we transfected the mutants and maintained the
cells for seven days at 31.8 °C. Hirt DNAwas treated with DpnI to reveal
newly synthesized viral DNA. Transfection of pIAMDV showed barely
any replicative form (RF) DNA from the AMDV genome (Fig. 6A, lane
4). RF DNA was detectable in samples from AAUAAA-mutated pIAMDV
clones (Fig. 6A, lanes 7–10 and lanes 13–18), and was not detected in
the NS1 knockout mutant (Fig. 6A, lane 6). This result suggests that
the activity of (pA)p has no signiﬁcant effect on the initial rounds of
viral DNA replication following transfection. However, for all the (pA)
p knockoutmutants, there was an increase in capsid protein expression
of, on average, ~2–3 fold (Fig. 6B, lane 3 vs. lanes 5–9), as well as an
increase in progeny virus production of ~3-fold (Fig. 6C). Furtherpassaging of the viruses produced from transfections revealed a clearer
picture than that seen during transfection. Approximately 3-fold of
increases in RF DNA, VP1/VP2, and progeny infectious virus were
consistently observed in infections of the AAUAAA-mutated AMDV-G
viruses (Figs. 6D–F).
Collectively, these results suggest that the knockout of the
AAUAAA signal in the (pA)p site signiﬁcantly increases the produc-
tion of infectious virus after a round of reinfection, probably due to
increased levels of VP1/VP2 resulting from increased production of
VP1/VP2-encoding mRNAs as well as from increased DNA replication.
Silent mutation of the DSE, which abrogates binding to CstF64, in the
AMDV infectious clone increases progeny virus production
An alternative approach to decreasing the polyadenylation of
AMDV pre-mRNA at the (pA)p site is to knock out its DSE. We intro-
duced ten silent mutations (one that would not affect the encoded
amino acids of VP1/2) in the identiﬁed 40 nt DSE (Fig. 7A). The cellular
protein CstF64 binds the DSE at the polyadenylation site and often
plays a role in regulating alternative polyadenylation (Zhao et al.,
1999). Thus, we examined the binding capability of the CstF64 to the
AMDV DSE and the silent mutant (smDSE) in vitro. The binding of
Fig. 4. Identiﬁcation of the USE of the AMDV internal polyadenylation site.(A) Schematic diagram of mutations upstream of the (pA)p site. The AMDV genome is shown, along with
its transcription units. Mutations in the region of nt 2324–2523 are diagrammed, with detailed sequences described in Materials and methods. The P(pA)p probe is also shown. (B)
RPA analysis. Ten μg of total RNA isolated from CMV-NSCap- or its mutant- transfected CrFK cells was used for the RPA, along with the P(pA)p probe. The origins of the two pro-
tected bands in the lanes are indicated to the right.
171Q. Huang et al. / Virology 426 (2012) 167–177CstF64 to the AMDV DSE RNA shifted the location of the 32P-labeled
DSE RNA to a position upstream from that of the free DSE RNA
(Fig. 7B, lane 2), but this shift (binding) could be competitively inhibited
by incubation with incubation of a 10 times excess of unlabeled AMDV
DSE RNA (Fig. 7B, lane 3). This result suggests that the AMDV DSE but
not the mutant smDSE (Fig. 7B, lanes 4–6) binds CstF64 speciﬁcally.
We next examined the polyadenylation efﬁciency of the smDSE
mutant in CrFK cells. Transfection of CMV-NSCap(smDSE) nearly
abolished polyadenylation of AMDV pre-mRNA at the (pA)p site
(Fig. 7C, lane 3 vs. lane 2), and produced ~2 times more VP1/VP2
than its non-mutated counterpart (Fig. 7D, lane 2). Furthermore,
this DSE silent mutation was introduced into pIAMDV and compared
with pIAMDV and pIAMDV[m(pA)p1] in terms of its effects on DNA
replication, VP1/VP2 expression and virus production. After transfec-
tion, we observed that pIAMDV(smDSE) replicated as well as pIAMDV
[m(pA)p1] (Fig. 8A, left panel, lanes 6 and 8). Furthermore,
pIAMDV(smDSE) produced ~4 times more VP1/VP2 than pIAMDV
(Fig. 8A, right panel, lane 3 vs. lane 2). We passaged the produced vi-
ruses in CrFK cells once. An average of ~3–4 times higher levels of RF
DNA and VP1/VP were detected in AMDV(smDSE)- and AMDV[m(pA)
p1]-infected cells than in AMDV-infected cells (Fig. 8B). In turn, the
number of progeny virus produced in AMDV(smDSE)- and AMDV
[m(pA)p1]-infected cells was ~2–3-fold that produced in AMDV-
infected cells (Fig. 8C). Again, these results strongly support the above
conclusion that preventing the polyadenylation of AMDV pre-mRNA
at the (pA)p site increases progeny virus production.Discussion
In this study, we have identiﬁed the USE and DSE that control
internal polyadenylation of the AMDV pre-mRNA at the (pA)p site.
Silent mutations of either the DSE or the AAUAAA hexanucleotide in
the context of an AMDV infectious clone abolished polyadenylation
of AMDV pre-mRNA at this site and facilitated progeny virus produc-
tion. Thus, our study reveals for the ﬁrst time the biological function
of internal polyadenylation during parvovirus infection. This has
implications for other parvoviruses, e.g., B19V and MVC, which also
use internal polyadenylation in the processing of their pre-mRNA.
The established B19V infectious clone is not efﬁcient, and produc-
tion of progeny virus is extremely low in the current culture system
(Zhi et al., 2004, 2006). This makes it practically impossible to exam-
ine the function of internal polyadenylation during B19V infection.
In MVC, a member of the genus Bocavirus, silent mutations at the
AAUAAA or the downstream region of the (pA)p site failed to knock
out polyadenylation at this site (Sun Y and Qiu J, unpublished obser-
vation), which also made it impossible to examine the function of
MVC internal polyadenylation during infection. The successful knock-
out of the (pA)p site in the AMDV infectious clone and identiﬁcation
of its function in progeny virus production may imply a common
mechanism underlying infection by parvoviruses with functional
(pA)p sites. Regulation of polyadenylation can be achieved in cis
through binding of CPSF160 to the AAUAAA hexanucleotide, binding
of CstF64 to the DSE, and binding of several factors to the USE (Zhao
Fig. 5.Mutagenesis analysis of the AAUAAA site.(A) Schematic diagram of mutations of the AAUAAA site. The AMDV genome is shown, along with its transcription units. Mutations
in the AAUAAA site are shown, as is the P(pA)p probe. (B) RPA analysis. Ten μg of total RNA isolated two days after transfection of CrFK cells with CMV-NSCap or mutant was used
for the RPA analysis, along with the probe p(PA)p. Lane 1, 32P-labeled RNA markers. The origins of the two protected bands in the lanes are indicated to the right. (C) Western blot
analysis. CrFK cells were transfected with CMV-NSCap or its mutants. At two days post-transfection, whole cell lysates were prepared and analyzed. The blot was probed using a
polyclonal antibody against VP2 (#2788). β-actin was probed as a loading control.
172 Q. Huang et al. / Virology 426 (2012) 167–177et al., 1999). The AMDV (pA)p site contains a consensus AAUAAA site,
in contrast to the nonconsensus AUUAAA in B19V pre-mRNA, indicat-
ing that it might be difﬁcult to regulate internal polyadenylation
through binding of the CPSF160 to this site. AMDV may have evolved
in such way so that it can regulate the internal polyadenylation
through factors binding to the DSE or USE site in different tissues or
animals at various ages during virus infection. We had tried to im-
prove the DSE to a consensus CstF64-binding sequence, for example,
5′GUUGUGGUGU3′ (Zarudnaya et al., 2003), at 15-nts downstream
of the AAUAAA site in the context of the non-replicative CMV-
NSCap construct. This mutation resulted in the polyadenylation of
almost all of the AMDV pre-mRNA at the (pA)p site (data not
shown). However, we were not able to introduce such a silent muta-
tion into the genome of the infectious clone. Notably, we found that
the DSE is conserved among various AMDV isolates (data not shown).
Collectively, these observations suggest that AMDV could have evolved
to sustain its replication at amoderate level in order tomaintain a status
of persistent infection through a conserved and functional DSE
sequence that binds to CstF64. The USE spans a large sequence of 200
nts, and a small region was not deﬁned (Fig. 4). We speculate there
are two ormore redundant positive control elements, or mixed positive
and negative control elements located in the USE, which warrants
further characterization.
A hallmark of AMDV infection in adult mink is persistent infection.
Viral production during such infection is restricted (Best and Bloom,
2005a), which may be beneﬁcial in terms of reduced neutralization
by neutralization antibodies and formation of immune complexes.
Permissive replication of AMDV in CrFK cells has been shown to
require the activation of caspases (Best et al., 2002), which can be ac-
tivated by the expression of AMDV capsid proteins (Cheng et al.,
2009). Caspases have been shown to cleave the large nonstructural
protein NS1 at two sites, D227 and D285, respectively. These cleavage
events were required for nuclear localization of the NS1 (Best et al.,
2003). In addition, active caspase cleaves VP1/VP2 at site of the417DLLD/G421 site, reducing production of full length of VP1 and
VP2 suitable for capsid assembly (Cheng et al., 2009). Therefore, there
must be a balance of capsid protein production, active caspase, and
functional NS1 for DNA replication. AMDV may ﬁnely tune the expres-
sion level of capsid proteins to activate caspases and assemble progeny
virions through the evolution of the (pA)p signal to an optimal level for
this expression.
The AMDV infectious clone replicates DNA and produces progeny
virus inefﬁciently after a single transfection (Bloom et al., 1990; Cheng
et al., 2009). Production of progeny virus requires at least one passage
of the virus produced from transfection but will eventually reach a
level akin to that from virus infection (Bloom et al., 1990; Cheng et al.,
2009). The exactmechanism underlying this phenomenon is unknown.
RF DNA is very hard to detect from transfection of the infectious clone.
The AUG translation initiation site for VP1/VP2 in the infectious clone
was knocked out, and we hoped to observe a single burst of DNA repli-
cation from the AMDV genome (without the potential for reinfection).
Such a single burst of DNA replication has been clearly shown with
the MVC infectious clone (Sun et al., 2009). However, RF DNA was not
detectable after transfectionwith the AMDVVP1/VP2-knockoutmutant
(data not shown). Thus, we believe that mutations of the AAUAAA and
DSE sites do not directly affect replication of AMDV RF DNA. An ~3–4-
fold increase in VP1/VP2 expression was observed in response to pre-
venting polyadenylation at the (pA)p site, which in turn increased the
level of DNA replication. This strongly suggests that increased levels
of VP1/VP2 result in increased assembly of empty virions to encapsi-
date the ssDNA genome generated from the replication of RF DNA,
and this in turn produces more progeny virus. The rolling-hairpin
replication model of parvoviral DNA (Cotmore and Tattersall,
2005) and several recent studies (Cheng et al., 2009; Plevka et al.,
2011) support the idea that the assembly of empty capsids is a pre-
requisite for parvoviral ssDNA production. It is highly possible that
there is a feedback mechanism between assembled empty capsids
and ssDNA production.
Fig. 6. Analysis of AAUAAA mutants in the AMDV-G infectious clone.(A) Southern blot analysis. Hirt DNA was isolated from CrFK cells infected with AMDV or transfected with
pIAMDV or its mutant. Samples were digested with or left undigested and subjected to Southern blotting. The blots were probed with a full-length AMDV probe. Arrow indicates
replicative form of the AMDV genome (RF DNA). Asterisk indicates digestion of an introduced DpnI site (GATC) in the (pA)p2 mutation (Fig. 5A). (B) Western blotting analysis.
Whole-cell lysates were prepared from the same CrFK cells infected with AMDV, or transfected with pIAMDV or its mutant, followed by Western blotting. The blots were probed
with an anti-VP2 polyclonal antibody (#2788). β-actin was used as a loading control. (C) Titration of progeny virus. CrFK cells were infected with AMDV, or transfected with
pIAMDV and its mutants, and were harvested at seven days post-treatment. The cells were frozen and thawed three times, and brieﬂy centrifuged. The supernatant was collected,
serially diluted, and used to infect CrFK cells in order to titrate FFU. FFU per ml is shown for infection from each virus preparation. (D–F) CrFK cells were infected with virus prep-
aration of AMDV-G and its mutants. At seven days post-infection, infected cells were collected. Hirt DNA, total protein, and virus production were analyzed by Southern blotting (D),
Western blotting (E), and virus titration (F), respectively, as described in panels A–C. Results shown in panels C and F represent the averages and S.D. from at least three indepen-
dent experiments. Pb0.05 as assessed based on the Student's t test.
173Q. Huang et al. / Virology 426 (2012) 167–177In conclusion, we have provided direct evidence for the ﬁrst time
that internal polyadenylation is a limiting step for parvovirus AMDV
production. This control mechanism might also be utilized by other
parvoviruses that use internal polyadenylation for pre-mRNA proces-
sing. These parvoviruses have evolved to maintain a persistent (or
regulated) infection. The genome of HBoV contains a (pA)p site that
is used during infection (Dijkman et al., 2009) and this site may
prevent excessive production of virus, according to results from spec-
imens from lower respiratory tract infections (Allander, 2008; Lin et
al., 2008). B19V may also use this post-transcriptional regulatory
approach to control progeny virus production (Guan et al., 2008).
Further investigations are warranted to examine these possibilities.Materials and methods
Cell and virus
The CrFK cells (Crandall feline kidney cell line, ATCC CCL-94) were
obtained from the American Type Culture Collection (ATCC, Manassas,
VA). Cells were maintained in Dulbecco's modiﬁed Eagle's medium
with 10% fetal calf serum at 37 °C in 5% CO2. The AMDV-G strain of
AMDVwas propagated and assayed in CrFK cells as previously reported
(Bloom et al., 1990, 1993; Mayer et al., 1983).Transfection and virus infection
CrFK cells were transfected using 2 μg of DNA per 60-mm plate
with Lipofectamine and Plus reagent (Invitrogen, Carlsbad, CA) as
described previously (Qiu and Pintel, 2002). CrFK cells were infected
with AMDV-G at a multiplicity of infection (MOI) of 1 [1 ﬂuorescence-
focus forming unit (FFU) per cell] (Bloom et al., 1980; Porter et al.,
1977).
Plasmid constructs
Construction of AMDV expression plasmids
CMV-NSCap-based plasmids. CMV-NSCap has been previously de-
scribed (Qiu et al., 2006a). The CMV-NSCap-based plasmids used to
examine downstream- and upstream-elements (DSE and USE) were
illustrated in Figs. 3 and 4. Detailed depictions of the mutations in
each of the regions are listed in Table 1. CMV-NSCap-based mutants
with mutations in the AAUAAA region are illustrated in Fig. 5. CMV-
NSCap(smDSE) was constructed by silently mutating the DSE at nt
2550–2576 as shown in Fig. 7.
pIAMDV-based plasmids. pIAMDV has been previously described
(Cheng et al., 2009). pIAMDV-based m(pA)p and smDSE mutants
Fig. 7. Analysis of the DSE silent mutant.(A) Sequence of the DSE silent mutation. A schematic diagram of the DSE silent mutation is shown above the AMDV genome and its tran-
scription units. The P(pA)p probe is shown. (B) In vitro gel shift analysis of CstF64 binding. AMDV DSE and smDSE RNAs were in vitro transcribed and labeled as described in
Materials and methods. The labeled RNA was incubated with puriﬁed human CstF64 or further incubated with 10 times more unlabelled RNA. The ﬁnal incubation mixtures
were analyzed on a 5% native polyacrylamide gel. The gel was autoradiographed using X-ray ﬁlm. Arrow indicates the shifted band. (C) RPA analysis. Ten μg of total RNA isolated
from CrFK cells transfected with CMV-NSCap and CMV-NSCap(smDSE) was protected using the P(pA)p probe. (D) Western blot analysis. CrFK cells were transfected with either
CMV-NSCap or the smDSE mutant. At two days post-transfection, whole-cell lysates were prepared and analyzed. The blot was probed using the anti-VP2 polyclonal antibody
#2788. β-actin was probed as a loading control.
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pIAMDV with their respective mutations in the CMV-NSCap-based
mutants. pIAMDV(NS1-) was constructed by mutating the G residues
at nt 404 and 407 to T in pIAMDV, which knocked out the expression
of the full-length NS1 (data not shown).
Clones used to generate probes for the RNase protection assay
RNase protection assay was used to map the transcription proﬁle
generated from transfection of CMV-NSCap. The probes used, PD1,
PA1, PA2, PD3, and PA3 (see Fig. 2A), were constructed as described
previously (Qiu et al., 2006a). Probe P(pA)p and its homologous
probes were made by cloning nt 2410–2642 of the AMDV-G genome
and the corresponding regions of AMDV-Gmutants with mutations at
the (pA)p site into BamHI-HindIII-digested pGEM4Z (Promega).
All of the AMDV-G nucleotide numbers (nt) used in this study
refer to Genbank accession no. JN040434 (Bloom et al., 1990). All of
the DNA constructs were sequenced at www.mclab.com to conﬁrm
that the mutations were as designed.
RNA isolation and RNase protection assay
Total RNAwas isolated using TRIzol® Reagent (Invitrogen, Carlsbad,
CA) (Guan et al., 2008). RNase protection assays were performed
with 10 μg of total RNA as previously described (Naeger et al., 1992;
Schoborg and Pintel, 1991). Probes were generated from linearized
templates using theMAXIscript® in vitro transcription kit fromAmbion
(Austin, TX). RNA hybridizations were carried out in substantial probe
excess, and signals were quantiﬁed with a Typhoon FLA 9000 Phosphor
Imager and ImageQuant™ TL (version 4.2.2) imaging software (GEHeath, Piscataway, NJ). Relative molar ratios of individual species of
RNAs were determined after adjustment for the number of 32P-labeled
uridines in each protected fragment, as previously described (Schoborg
and Pintel, 1991).
Southern blot analysis
AMDV-G replicative form (RF) DNA produced from transfection
or infection was visualized by Southern blot analysis. Hirt DNA was
isolated from transfected or infected cells by the Hirt extraction
method, as previously described (Qiu et al., 2006a). Samples were
run on a 1% agarose gel, and Southern blotting was performed as
described previously (Naeger et al., 1990; Tullis et al., 1993), using
the AMDV-G DNA of nt 1–4722. Blots were exposed to a GE Health
Care phosphor imaging screen, and the DNA forms were quantiﬁed
using a Typhoon FLA 9000 Phosphor Imager and ImageQuant™ TL
(version 4.2.2) imaging software (GE Health Care).
Western blot analysis
Western blotting was performed on cell extracts taken at seven
days post-infection or two days post-transfection. Whole-cell lysate
was prepared as previously described (Qiu et al., 2006a). Samples
were subjected to immunoblotting as previously described (Liu et
al., 2004), using a polyclonal antibody (#2788) against AMDV VP2
amino acids 428–446 (Cheng et al., 2009). Anti-β-actin monoclonal
antibody was purchased from Sigma (St. Louis, MO). Signals were
developed using SuperSignal West Dura Chemiluminescent Substrate
(ThermoFisher Scientiﬁc, Waltham, MA). The images were taken
Fig. 8. Analysis of the DSE silent mutant in the context of an AMDV infectious clone.(A) Southern blot andWestern blot analysis of transfected cells. CrFK cells were transfected with
pIAMDV, pIAMDV(smDSE) and pIAMDV[m(pA)p1]. At seven days post-transfection, transfected cells were collected and used to prepare Hirt DNA and total protein. Hirt DNA was
digested with DpnI or left undigested for Southern blotting. The blots were probed with a full-length AMDV probe. Whole-cell lysates were used for Western blotting. The blots
were probed with the anti-VP2 polyclonal antibody #2788. β-actin was used as a loading control. (B) Southern blot and Western blot analysis of infected cells. CrFK cells were
infected with AMDV-G, AMDV-G(smDSE) and AMDV-G[m(pA)p1]. At seven days post-infection, infected cells were collected and used to prepare Hirt DNA and whole-cell lysate.
Hirt DNA samples were digested with DpnI or left undigested for Southern blotting. The blots were probed with a full-length AMDV probe. Whole-cell lysates were used forWestern
blotting. The blots were probed with an anti-VP2 polyclonal antibody. β-actin was used as a loading control. (C) Titration of progeny virus. CrFK cells were infected with AMDV,
AMDV(smDSE), or AMDV[m(pA)p1], and were harvested at seven days post-treatment. The cells were frozen and thawed three times, and brieﬂy centrifuged. The supernatant
was collected, serially diluted, and used to infect CrFK cells in order to titrate FFU. FFU per ml is shown for each infection. Results shown represent the averages and S.D. from at
least three independent experiments. Pb0.05 as assessed based on the Student's t test.
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Gauge v2.3 software.
Fluorescence focus-forming assay to titrate virus production
Virus titers were determined according to FFU in CrFK cells at
31.8 °C as previously reported (Bloom et al., 1980; Porter et al.,
1977). Brieﬂy, 4-well chamber slides (Lab Tek II, Nunc) were seeded
with CrFK cells at a density 5.0×105 cells/well, and incubated for
24 h at 37 °C in 5% CO2, to produce a conﬂuent monolayer. The virus
sample was titrated 10-fold and used to infect the cell monolayer in
a volume of 0.1 ml. The infected monolayer was incubated at 31.8 °C
in 5% CO2. After 6 days of infection, an immunoﬂuorenscence assay
was carried out on the infected cells. Overlay medium was removed
from the wells and replaced with cold phosphate-buffered saline
(PBS). After 5 min incubation on ice, cells were ﬁxed for 10 min in
ice-cold acetone and then washed with PBS. The cells were incubated
with antibody #2788 at a dilution of 1:100 in PBS containing 0.2% BSA(PBS-BSA) for 1 h at room temperature and then washed three times
with PBS-BSA. Antibody-labeled cells were detected through the
incubation of the cells for 1 h with a secondary antibody conjugated
with FITC (at a dilution of 1:100 in PBS-BSA), followed by washing
three times with PBS-BSA. Cells that were labeled with ﬂuorescent
antibody were visualized under a NIKON Ti S inverted ﬂuorescence
microscope with a Photometrics HQ2 dual model B&W low light
CCD camera. Fluorescence foci located within each well were
counted, and virus titers were calculated and expressed as FFU per ml.
Flag-tagged CstF64 protein expression and puriﬁcation
Full-length cDNA encoding human cleavage stimulation factor-64
(CstF64)was provided fromDr. Clinton C.MacDonald (Dass et al., 2001).
The C-terminal ﬂag-tagged CstF64 ORF was inserted into the plasmid
pLenti-MCS-IRES-GFP-WPRE, generating the plasmid pLenti-CstF64-
Flag. The pLenti-MCS-IRES-GFP-WPRE was constructed by modifying
sequences downstream from the CMV promoter in pLenti-GFP-Puro
Table 1
Plasmid construction.
Construct name Sequence on AMDV-G
(JN040434)
Sequence on Lambda DNA (J02459.1)
CMV-NSCap(mDSE1-200) nt 2544–2743 401–600
CMV-NSCap(mDSE101-200) nt 2644–2743 501–600
CMV-NSCap(mDSE1-100) nt 2544–2643 401–500
CMV-NSCap(mDSE70-100) nt 2613–2643 470–500
CMV-NSCap(mDSE1-69) nt 2544–2612 401–469
CMV-NSCap(mDSE41-69) nt 2584–2612 5′ctggatctcagtgcgctgctggcgagcct3′
CMV-NSCap(mDSE1-40) nt 2544–2583 401–440
CMV-NSCap(mDSE7-20) nt 2550–2563 5′TCTCGCGCGCGCGCG3′
CMV-NSCap(mDSE1-20) nt 2544–2563 401–420
CMV-NSCap(mDSE21-40) nt 2564–2583 5′ccacccaccaaccaaacacc3′
CMV-NSCap(mDSE0-7) nt 2543–2549 ATTACTT
CMV-NSCap(mDSE7-20b) nt 2550–2563 5′CACAAGAGGACGGCA3′
CMV-NSCap(mUSE200-1) nt 2324–2523 401–600
CMV-NSCap(mUSE200-89) nt 2324–2435 401–512
CMV-NSCap(mUSE 88–1) nt 2436–2523 513–600
CMV-NSCap(mUSE 88–53) nt 2436–2471 513–548
CMV-NSCap(mUSE 52–1) nt 2472–2523 549–600
176 Q. Huang et al. / Virology 426 (2012) 167–177(#17448, Addgene, Cambridge, MA) with, in order, a multiple cloning
site (MCS, BamH-EcoRI-EcoRV-SpeI-SalI), IRES-GFP (from pIRES2-EGFP,
Clontech) and the WPRE (Woodchuck post-transcriptional element).
FreeStyle™ 293-F cells were cultured in suspension in FreeStyle™ 293
Expression Medium and transfected with the FreeStyle™MAX Reagent
following the manufacturers' instructions (Invitrogen). At two days
post-transfection, the cells were collected. CstF64-Flag protein was
puriﬁed using anti-Flag® M2 afﬁnity gel (Sigma) according to the
manufacturer's instructions. Brieﬂy, the conditionedmedium contain-
ing CstF64-Flag and proteinase inhibitors was incubated overnight at
4 °C with the appropriate amount of anti-Flag M2 afﬁnity gel in the
conditionedmedium. After incubation, the resin was collected by ﬁltra-
tion through a chromatography column and washed. The CstF64-Flag
protein was then eluted with 3×Flag peptide in TBS (pH 7.5). BSA
(1 mg/ml) was added to the protein before being storage at −80 °C.
The puriﬁed proteins were quantiﬁed by Western blot with Flag-
BAP™ protein (Sigma) as a standard using anti-Flag® M2 antibody
(Strategene).
RNA gel shift analysis
An RNA sequence (probe) spanning either the DSE or the silently
mutated DSE (smDSE) region (nt 2487–2615) was generated from
linearized templates using the MAXIscript® in vitro transcription kit
from Ambion (Austin, TX). Approximately (~)0.5 μg of CstF64-Flag
protein and 32P-UTP-labeled RNA probe (~15,000 cpm) were incu-
bated in the binding buffer (20 mM Tris–HCl pH 7.6, 0.5 mM EDTA,
0.5 mM dithiothreitol, 10% glycerol, 30 mM KCl, 3 mM MgCl2) at
room temperature for 20 min. The samples were then separated in a
5% non-denaturing polyacrylamide gel in 0.5×TBE buffer at 120 V
for 2 h. The gels were then dried and exposed to radiographic ﬁlms.
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